Atara Biotherapeutics (NASDAQ:ATRA) Upgraded by RODMAN&RENSHAW to Strong-Buy Rating

Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by investment analysts at RODMAN&RENSHAW to a “strong-buy” rating in a report released on Friday,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. Canaccord Genuity Group raised their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Rodman & Renshaw began coverage on Atara Biotherapeutics in a report on Friday. They set a “buy” rating and a $25.00 target price on the stock. Finally, TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Atara Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $18.75.

Atara Biotherapeutics Stock Up 14.8 %

NASDAQ ATRA opened at $11.40 on Friday. The company has a market cap of $65.66 million, a price-to-earnings ratio of -0.44 and a beta of 0.55. Atara Biotherapeutics has a twelve month low of $6.50 and a twelve month high of $39.50. The business’s fifty day moving average is $10.80 and its 200 day moving average is $9.60.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The firm had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same period in the previous year, the business posted ($16.50) earnings per share. On average, research analysts anticipate that Atara Biotherapeutics will post -12.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atara Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ATRA. Vestal Point Capital LP increased its holdings in Atara Biotherapeutics by 11.3% in the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after purchasing an additional 12,677 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in Atara Biotherapeutics during the second quarter worth $79,000. State Street Corp grew its holdings in Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares during the period. FMR LLC increased its stake in Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Atara Biotherapeutics during the 2nd quarter worth about $53,000. Institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.